- ￥1668
- abinScience
- China
- VA411023
- 2025年10月20日
- ELISA, Neutralization
- Alpaca
- Vaccinia virus (VACV)
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Alpaca
- 亚型：
VHH-His
- 形态：
Liquid
- 克隆性：
Monoclonal
- 标记物：
Unconjugated
- 适应物种：
Vaccinia virus (VACV)
- 保质期：
1 year
- 抗原来源：
Alpaca
- 目录编号：
VA411023
- 级别：
科研级别
- 库存：
999
- 供应商：
abinScience
- 宿主：
Alpaca
- 应用范围：
ELISA, Neutralization
- 浓度：
1mg/mL
- 靶点：
G9&A16 complex
- 抗体英文名：
Anti-VACV G9&A16 complex Nanobody (SAA2378)
- 抗体名：
Anti-VACV G9&A16 complex Nanobody (SAA2378)
- 规格：
100ug
| Product name | Anti-VACV G9&A16 complex Nanobody (SAA2378) |
|---|---|
| Catalog No. | VA411023 |
| Host species | Alpaca |
| Species reactivity | Vaccinia virus (VACV) |
| Immunogen | / |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4 |
| Purity | >95% as determined by SDS-PAGE. |
| Clonality | Monoclonal |
| Isotype | VHH-His |
| Applications | ELISA, Neutralization |
| Target | Entry-fusion complex protein OPG094, EFC protein OPG094, Myristoylated protein G9, Protein F1, OPG094, Virion membrane protein A16 |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | P07611 & O93122 |
| Accession.1 | P07611 & O93122 |
| Alternative Names | / |
| Clone ID | SAA2378 |
| Note | For research use only |
abinScience, founded in 2023 in Strasbourg, France, is committed to developing and producing high-quality life science reagents. Rooted in one of Europe’s leading hubs for scientific innovation, abinScience empowers global research through reliable, efficient experimental solutions. Guided by the vision of “Empowering Bioscience Discovery,” we support scientists worldwide in advancing the frontiers of bioscience.
Technology and Innovation
Relying on the global leading position in antibody and protein research and more than 20 years of industry experience of its parent company ProteoGenix since 2003, abinScience has inherited advanced technologies and high-quality standards. In particular, the XtenCHO™ system developed by ProteoGenix, which has two modes of transient expression and stable expression, has been widely recognized as a core technology to improve the efficiency of protein production, providing a solid foundation for ab...
Product categories and application fields.
Main products.
10000+ high-activity proteins.
15000+ antibody series products:
Classic monoclonal antibody.
Monoclonal antibody
Internal control antibody, labeled antibody.
High-quality phosphorylation antibodies.
Highly specific nanobodies and small molecule antibodies.
Functional antibodies in vivo.
Low-background flow cytometry antibodies.
DNA/RNA antibodies and PEG antibodies.
1000+ reagent kit series products.
Large-scale packaging customization services: We offer personalized antibody design, protein production, molecular optimization, and experimental development services.
Application field
Infectious disease research: including viruses, superbugs, parasites, etc.
Neuroscience research: Supporting research on neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
Immunology research: Covers the research needs of immune activation, inhibition, and allergies and abnormal reactions.
Oncology research: Supporting the development of tumor biology and anti-tumor drugs.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验• Structural basis of poxvirus fusion regulation and anti-A16/G9 antibody-mediated neutralization and protection., PMID:40865523
• Vaccinia mature virus fusion regulator A26 protein binds to A16 and G9 proteins of the viral entry fusion complex and dissociates from mature virions at low pH., PMID:22278246
• Vaccinia virus A56/K2 fusion regulatory protein interacts with the A16 and G9 subunits of the entry fusion complex., PMID:18353946
• Structural dissection of vaccinia G9 identifies residues essential for membrane fusion and complex assembly., PMID:40824092
• Experimental Evolution To Isolate Vaccinia Virus Adaptive G9 Mutants That Overcome Membrane Fusion Inhibition via the Vaccinia Virus A56/K2 Protein Complex., PMID:32132237
• Poxvirus multiprotein entry-fusion complex., PMID:16339313
• Mutations Near the N Terminus of Vaccinia Virus G9 Protein Overcome Restrictions on Cell Entry and Syncytium Formation Imposed by the A56/K2 Fusion Regulatory Complex., PMID:32132239
• Widespread Distribution and Evolution of Poxviral Entry-Fusion Complex Proteins in Giant Viruses., PMID:36912656
• Structural and functional analysis of vaccinia viral fusion complex component protein A28 through NMR and molecular dynamic simulations., PMID:37948471
技术资料暂无技术资料 索取技术资料
